Episodes

  • Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer

    Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Lung Cancer
    Nov 16 2024
    Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.
    Show more Show less
    1 hr and 6 mins
  • The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review

    The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review
    Oct 23 2024
    Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.
    Show more Show less
    43 mins
  • The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer

    The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer
    Oct 16 2024
    Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.
    Show more Show less
    1 hr
  • The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR

    The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR
    Oct 8 2024
    Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.
    Show more Show less
    58 mins
  • The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations

    The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations
    Oct 2 2024
    Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.
    Show more Show less
    58 mins
  • Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors

    Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors
    Sep 19 2024
    Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
    Show more Show less
    59 mins
  • Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

    Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation
    Sep 12 2024
    Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.
    Show more Show less
    2 hrs and 3 mins